Last reviewed · How we verify
NMRA-335140
NMRA-335140 is a selective serotonin 5-HT7 receptor antagonist designed to modulate mood and emotional processing through central nervous system effects.
NMRA-335140 is a selective serotonin 5-HT7 receptor antagonist designed to modulate mood and emotional processing through central nervous system effects. Used for Major depressive disorder.
At a glance
| Generic name | NMRA-335140 |
|---|---|
| Also known as | BTRX 335140, CYM-53093, Navacaprant, BTRX-335140 |
| Sponsor | Neumora Therapeutics, Inc. |
| Drug class | 5-HT7 receptor antagonist |
| Target | 5-HT7 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
The drug targets the 5-HT7 receptor, a serotonin receptor subtype implicated in mood regulation, circadian rhythm control, and emotional processing. By antagonizing this receptor, NMRA-335140 aims to provide therapeutic benefits in psychiatric and neurological conditions. This mechanism represents a novel approach to treating mood disorders through a less commonly targeted serotonergic pathway.
Approved indications
- Major depressive disorder
Common side effects
- Headache
- Nausea
- Dizziness
- Insomnia
Key clinical trials
- Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (PHASE3)
- Study to Assess the Safety and Effectiveness of NMRA-335140-501 (PHASE3)
- Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder (PHASE3)
- Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (PHASE3)
- To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder. (PHASE2)
- Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NMRA-335140 CI brief — competitive landscape report
- NMRA-335140 updates RSS · CI watch RSS
- Neumora Therapeutics, Inc. portfolio CI